Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
2.
Clin Dermatol ; 41(4): 476-480, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37574152

RESUMO

Eyelid dermatitis may present with a variety of clinical findings including erythema, pruritus, and edema, and it has a wide differential. Allergic contact dermatitis due to allergen sources in personal care products, cosmetics, and fragrances is a leading cause of eyelid dermatitis and may be challenging to diagnose by clinical examination alone. Expanded patch testing, in addition to careful inspection of the surrounding skin for additional areas of involvement and clinical clues, remains an important tool in differentiating allergic contact dermatitis from other relevant etiologies of eyelid dermatitis including irritant contact dermatitis, atopic dermatitis, seborrheic dermatitis, and rosacea. We present a practical approach to the management of eyelid dermatitis including the use of a topical anti-inflammatory for long-term control of eyelid findings. Further diagnostic workup may be warranted in patients with refractory eyelid dermatitis.


Assuntos
Blefarite , Cosméticos , Dermatite Alérgica de Contato , Dermatite Atópica , Humanos , Dermatite Alérgica de Contato/diagnóstico , Dermatite Alérgica de Contato/etiologia , Dermatite Atópica/diagnóstico , Pálpebras , Alérgenos/efeitos adversos , Cosméticos/efeitos adversos , Testes do Emplastro/efeitos adversos , Blefarite/diagnóstico , Blefarite/etiologia , Blefarite/terapia
7.
Am J Clin Dermatol ; 23(1): 61-67, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34855151

RESUMO

Dupilumab facial redness (DFR), or the development of an eczematous rash of the face and neck with dupilumab use, has been observed in recent case reports. It is estimated to impact between 4 and 43.8% of dupilumab users, including children and adults. Aside from reviewing the pathogenesis and clinical presentation, we present potential diagnostic steps (such as skin scraping, serologies, biopsy, and patch testing) and management options for DFR ranging from allergen avoidance to dupilumab interruption. It is hoped that this article will serve as a means for clinicians to familiarize themselves with DFR regarding the differential diagnosis, diagnostic tools, and treatment options associated with this phenomenon.


Assuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Eritema/induzido quimicamente , Dermatoses Faciais/induzido quimicamente , Administração Tópica , Antibacterianos/uso terapêutico , Antifúngicos/uso terapêutico , Inibidores de Calcineurina/uso terapêutico , Diagnóstico Diferencial , Toxidermias/diagnóstico , Eritema/terapia , Dermatoses Faciais/terapia , Glucocorticoides/uso terapêutico , Humanos , Testes Cutâneos
8.
Arch Dermatol Res ; 314(8): 805-808, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33772628

RESUMO

Statins have been associated with an increased risk of keratinocyte carcinoma but data are limited and conflicting. Statins are hypothesized to contribute to KC through immunomodulation. A whole-population case-control study of the Icelandic population was conducted using the Icelandic Cancer Registry and Icelandic Prescription Medicine Register. These are high-quality registers which include all cancer diagnoses, as well as every prescription in the country. Cases included all first-time histologically confirmed diagnoses of (BCC), in situ squamous cell carcinoma (SCCis) and invasive SCC between 2003 and 2017. Each case was paired with 10 age- and sex-matched controls. Multivariate conditional logistic regression analysis was performed. Four thousand seven hundred patients with BCC, 1167 patients with SCCis and 1013 patients with invasive SCC were identified and paired with 47,292, 11,961 and 10,367 controls, respectively. Overall statin use was associated with an increased risk of invasive SCC and SCCis but not BCC (adjusted OR [95% CI]: 1.29 [1.11-1.50]; 1.43 [1.24-1.64]; 1.03 [0.95-1.12], respectively). Subgroup analysis demonstrated that statins were significantly associated with invasive SCC and SCCis in patients over 60, but not in those under 60. Atorvastatin was only associated with an increased risk of SCCis; whereas, simvastatin was associated with an increased risk of both invasive SCC and SCCis. This whole-population study of Iceland demonstrates that statin exposure is associated with increased risk of SCC, but not BCC, in a low UV environment. The reasons are unclear, but our results may suggest that individuals receiving atorvastatin and simvastatin have differing levels of baseline keratinocyte cancer risk or that properties of a statin other than 'statin intensity' affect association with SCC.


Assuntos
Carcinoma Basocelular , Carcinoma de Células Escamosas , Inibidores de Hidroximetilglutaril-CoA Redutases , Neoplasias Cutâneas , Atorvastatina , Carcinoma Basocelular/patologia , Carcinoma de Células Escamosas/epidemiologia , Carcinoma de Células Escamosas/patologia , Estudos de Casos e Controles , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Islândia/epidemiologia , Sinvastatina , Neoplasias Cutâneas/induzido quimicamente , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/patologia
10.
J Am Acad Dermatol ; 86(3): 515-524, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-34915056

RESUMO

Despite advances in early detection as described in part 1 of this continuing medical education series, melanoma continues to be a large contributor to cutaneous cancer-related mortality. In a subset of patients with unresectable or metastatic disease, surgical clearance is often not possible; therefore, systemic and local therapies are considered. The second article in this series provides dermatologists with an up-to-date working knowledge of the treatment options that may be prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma.


Assuntos
Melanoma/terapia , Recidiva Local de Neoplasia/terapia , Neoplasias Cutâneas/terapia , Educação Médica Continuada , Humanos , Imunoterapia , Melanoma/patologia , Recidiva Local de Neoplasia/patologia , Neoplasias Cutâneas/patologia
11.
J Am Acad Dermatol ; 86(3): 503-512, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-34915058

RESUMO

In response to rising rates of melanoma worldwide, novel noninvasive melanoma detection techniques are emerging to facilitate the early detection of melanoma and decrease unnecessary biopsies of benign pigmented lesions. Because they often report similar study findings, it may be difficult to determine how best to incorporate these technologies into clinical practice based on their supporting studies alone. The first article in this continuing medical education series provides practical advice on how and when to use various noninvasive melanoma detection techniques in clinical practice.


Assuntos
Melanoma , Neoplasias Cutâneas , Biópsia , Dermoscopia/métodos , Humanos , Melanoma/diagnóstico , Melanoma/patologia , Microscopia Confocal/métodos , Sensibilidade e Especificidade , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/patologia
12.
Clin Dermatol ; 39(5): 757-761, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34785003

RESUMO

Water has numerous functions necessary for survival including cellular homeostasis, solvent properties for dissolving ions and solutes, thermoregulation, and transport of waste and nutrients. Despite the established beneficial role of water in skin physiology, the optimal methods for skin hydration and requirements for daily water consumption remain elusive. This review summarizes the cellular and molecular biology of skin hydration, the debate and current recommendations of daily water requirements, and the latest research on interventions to improve skin hydration by both internal and external means of water exposure. We also explore the chemical properties of water, such as the concept of water "hardness" and environmental pollutants, and their impact on skin physiology.


Assuntos
Fenômenos Fisiológicos da Pele , Água , Humanos , Pele
13.
Clin Dermatol ; 39(5): 762-771, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34785004

RESUMO

Cigarette and electronic cigarette use are significant public health concerns across the United States. Tobacco use remains the single most preventable cause of morbidity and mortality in the world. Electronic cigarettes initially emerged as a better alternative to conventional cigarettes and for promoting smoking cessation; however, current evidence reveals similar deleterious health implications caused by both products on almost all organ systems, including the skin. Recognition of the cutaneous manifestations associated with cigarette and electronic cigarette use is essential for dermatologists in current clinical practice. Dermatologists play a vital role in educating and counseling patients on smoking cessation. We specifically highlight the cutaneous consequences of conventional cigarette smoking and electronic cigarettes on dermatologic disease.


Assuntos
Sistemas Eletrônicos de Liberação de Nicotina , Produtos do Tabaco , Vaping , Humanos , Nicotiana , Uso de Tabaco , Estados Unidos/epidemiologia , Vaping/efeitos adversos
19.
J Am Acad Dermatol ; 85(1): 56-61, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33610593

RESUMO

BACKGROUND: Metformin has anticarcinogenic properties and is also known to inhibit the sonic hedgehog pathway, but population-based studies analyzing the potential protective effect for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are needed. OBJECTIVES: To delineate the association between metformin use and invasive SCC, SCC in situ (SCCis), and BCC. METHODS: A population-based case-control study design was employed using all 6880 patients diagnosed in Iceland between 2003-2017 with first-time BCC, SCCis, or invasive SCC, and 69,620 population controls. Multivariate odds ratios (ORs) were calculated using conditional logistic regression. RESULTS: Metformin was associated with a lower risk of developing BCC (OR, 0.71; 95% confidence interval [CI], 0.61-0.83), even at low doses. No increased risk of developing SCC was observed. SCCis risk was mildly elevated in the 501-1500 daily dose unit category (OR, 1.40; 95% CI, 1.00-1.96). LIMITATIONS: This study was retrospective in nature with the inability to adjust for ultraviolet exposure, Fitzpatrick skin type, and comorbidities. CONCLUSION: Metformin is associated with decreased risk of BCC development, even at low doses. Metformin might have potential as a chemoprotective agent for patients at high risk of BCC, although this will need confirmation in future studies.


Assuntos
Carcinoma Basocelular/epidemiologia , Metformina/uso terapêutico , Neoplasias Cutâneas/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Carcinoma Basocelular/patologia , Carcinoma Basocelular/prevenção & controle , Estudos de Casos e Controles , Feminino , Proteínas Hedgehog/antagonistas & inibidores , Proteínas Hedgehog/metabolismo , Humanos , Islândia/epidemiologia , Masculino , Metformina/farmacologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/efeitos da radiação , Pele/efeitos dos fármacos , Pele/patologia , Pele/efeitos da radiação , Neoplasias Cutâneas/etiologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/prevenção & controle , Raios Ultravioleta/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...